Bright Minds Biosciences Inc. (DRUG)
NASDAQ: DRUG · Real-Time Price · USD
85.48
-0.60 (-0.70%)
At close: Feb 20, 2026, 4:00 PM EST
83.50
-1.98 (-2.32%)
After-hours: Feb 20, 2026, 7:32 PM EST

Bright Minds Biosciences Cash Flow Statement

Millions CAD. Fiscal year is Oct - Sep.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Sep '25 Sep '24 Sep '23 Sep '22 Sep '21
Net Income
-19.84-12.23-2.8-7.37-14.96-8.65
Depreciation & Amortization
0.080.080.070.070.01-
Asset Writedown & Restructuring Costs
----0-
Stock-Based Compensation
4.293.180.841.150.90.88
Other Operating Activities
2.79-0.28-00.07-0.260.14
Change in Accounts Payable
1.031.690.24-1.20.770.51
Change in Other Net Operating Assets
-1.35-1.13-0.20.26-0.04-0.2
Operating Cash Flow
-13.01-8.69-1.85-7.02-13.59-7.32
Long-Term Debt Repaid
--0.1-0.09-0.09-0.01-
Net Debt Issued (Repaid)
-0.1-0.1-0.09-0.09-0.01-
Issuance of Common Stock
50.4286.030.91.47627.84
Other Financing Activities
-3.4-0.36-0.8-0.8-1.79
Financing Cash Flow
46.9285.570.812.195.226.06
Foreign Exchange Rate Adjustments
-2.750.310.01-0.050.260.22
Net Cash Flow
31.1577.19-1.03-4.88-8.1318.96
Levered Free Cash Flow
-7.7-4.6-0.69-4.22-7.58-3.85
Unlevered Free Cash Flow
-7.67-4.58-0.69-4.22-7.58-3.85
Change in Working Capital
-0.320.550.04-0.940.720.31
Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q